Skip to content

Study · Not a test of the peptide alone · 2022

6 results

Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial.

Li X, Li H, Shi H, Li X, Zhou R, Lu D, Cai Y, Zhou Y, Cabri P, Shi X, Pedret-Dunn A, Leng J

Advances in therapy10 Aug 2022Cited by 7 (Europe PMC)

PMID35947347 (opens in a new tab)PMCIDPMC9464738 (opens in a new tab)DOI10.1007/s12325-022-02264-5 (opens in a new tab)PepBankPUB-35947347
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In women with endometriosis, triptorelin pamoate was noninferior to acetate, with over 98% chemically castrated in both groups at week 12.

    In plain wordsIn women with endometriosis, triptorelin pamoate and acetate suppressed estradiol similarly, with over 98% chemically castrated at week 12.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeEstradiol suppression to castration levels
    Study

    n = 300

    Comparator
    Triptorelin acetate PR 1-month
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Chemical castration
    > 98%
    both formulations at week 12

    Source sentences

    Summary
    Triptorelin pamoate PR 3-month was noninferior to triptorelin acetate PR 1-month for the treatment of endometriosis: over 98% of patients in both groups were chemically castrated at week 12.
    2 context sentences
    Summary · context
    The trial was conducted in 24 clinical centers in China, and included 300 Chinese women (18-45 years) with endometriosis and regular menstrual cycles who required treatment with a gonadotropin-releasing hormone agonist for 6 months.
    Summary · context
    One group of patients (n = 150) was treated with triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks), and the other (n = 150) with triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In women with endometriosis, triptorelin pamoate and acetate were equally efficacious in reducing associated pelvic pain.

    In plain wordsIn women with endometriosis, triptorelin pamoate and acetate reduced pelvic pain equally.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePelvic pain
    Study

    n = 300

    Comparator
    Triptorelin acetate PR 1-month
    Outcome group
    Pain · Reproductive and sexual health

    Source sentences

    Summary
    Both formulations were also equally efficacious in reducing endometriosis-associated pelvic pain, and reducing serum concentrations of E2, luteinizing hormone, and follicle-stimulating hormone over time.
    2 context sentences
    Summary · context
    The trial was conducted in 24 clinical centers in China, and included 300 Chinese women (18-45 years) with endometriosis and regular menstrual cycles who required treatment with a gonadotropin-releasing hormone agonist for 6 months.
    Summary · context
    One group of patients (n = 150) was treated with triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks), and the other (n = 150) with triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In women with endometriosis, triptorelin pamoate and acetate were equally efficacious in reducing serum estradiol over time.

    In plain wordsIn women with endometriosis, triptorelin pamoate and acetate reduced estradiol equally.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeSerum estradiol
    Study

    n = 300

    Comparator
    Triptorelin acetate PR 1-month
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Both formulations were also equally efficacious in reducing endometriosis-associated pelvic pain, and reducing serum concentrations of E2, luteinizing hormone, and follicle-stimulating hormone over time.
    2 context sentences
    Summary · context
    The trial was conducted in 24 clinical centers in China, and included 300 Chinese women (18-45 years) with endometriosis and regular menstrual cycles who required treatment with a gonadotropin-releasing hormone agonist for 6 months.
    Summary · context
    One group of patients (n = 150) was treated with triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks), and the other (n = 150) with triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In women with endometriosis, triptorelin pamoate and acetate were equally efficacious in reducing serum luteinizing hormone over time.

    In plain wordsIn women with endometriosis, triptorelin pamoate and acetate reduced luteinizing hormone equally.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeSerum luteinizing hormone
    Study

    n = 300

    Comparator
    Triptorelin acetate PR 1-month
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Both formulations were also equally efficacious in reducing endometriosis-associated pelvic pain, and reducing serum concentrations of E2, luteinizing hormone, and follicle-stimulating hormone over time.
    2 context sentences
    Summary · context
    The trial was conducted in 24 clinical centers in China, and included 300 Chinese women (18-45 years) with endometriosis and regular menstrual cycles who required treatment with a gonadotropin-releasing hormone agonist for 6 months.
    Summary · context
    One group of patients (n = 150) was treated with triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks), and the other (n = 150) with triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In women with endometriosis, triptorelin pamoate and acetate were equally efficacious in reducing serum follicle-stimulating hormone over time.

    In plain wordsIn women with endometriosis, triptorelin pamoate and acetate reduced follicle-stimulating hormone equally.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeSerum follicle-stimulating hormone
    Study

    n = 300

    Comparator
    Triptorelin acetate PR 1-month
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Both formulations were also equally efficacious in reducing endometriosis-associated pelvic pain, and reducing serum concentrations of E2, luteinizing hormone, and follicle-stimulating hormone over time.
    2 context sentences
    Summary · context
    The trial was conducted in 24 clinical centers in China, and included 300 Chinese women (18-45 years) with endometriosis and regular menstrual cycles who required treatment with a gonadotropin-releasing hormone agonist for 6 months.
    Summary · context
    One group of patients (n = 150) was treated with triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks), and the other (n = 150) with triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  6. 06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome

    In women with endometriosis treated with triptorelin formulations, no new safety concerns were identified.

    In plain wordsIn women with endometriosis treated with triptorelin formulations, no new safety concerns were identified.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableNew safety concerns
    Study

    n = 300

    Outcome group
    Adverse events · Reproductive and sexual health

    Source sentences

    Summary
    No new safety concerns were identified.
    2 context sentences
    Summary · context
    The trial was conducted in 24 clinical centers in China, and included 300 Chinese women (18-45 years) with endometriosis and regular menstrual cycles who required treatment with a gonadotropin-releasing hormone agonist for 6 months.
    Summary · context
    One group of patients (n = 150) was treated with triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks), and the other (n = 150) with triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks).

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03232281

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Ipsenn = 30028 Jul 2017 to 16 Nov 2019

Endometriosis

Trial pageClinicalTrials.govUpdated 14 Oct 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.